Results 221 to 230 of about 461,280 (380)

Clinical and Molecular Genetic Characterization of Landau Kleffner Syndrome: An Observational Cohort and Experimental Study

open access: yesAnnals of Neurology, EarlyView.
Objective Landau–Kleffner syndrome (LKS), is a rare, poorly‐understood epileptic encephalopathy with spike–wave activation in sleep associated with mutations in GRIN2A, encoding the N‐Methyl‐D‐Aspartate receptor (NMDAR) GluN2A subunit. Physicians rely on empirical treatments, with scarce information on treatment efficacy and outcomes.
Adeline Ngoh   +15 more
wiley   +1 more source

Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations

open access: yesAnnals of Neurology, EarlyView.
Objectives To examine volumetric magnetic resonance imaging (vMRI) in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD), compared to multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and healthy controls (HC). Methods Standardized vMRI in MOGAD were compared to age, sex, and disease duration matched MS (5:1),
Amy Kunchok   +10 more
wiley   +1 more source

Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial. [PDF]

open access: yesJ Neurol
Romanò F   +21 more
europepmc   +1 more source

Subthalamic Electrophysiological Mapping of Gait Initiation Dynamics and Freezing in Parkinson's Disease

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to investigate the relationships among subthalamic nucleus (STN) activity, gait initiation (GI), and freezing of gait (FOG) in patients with Parkinson's disease (PD). Methods We recorded GI and STN local field potentials (LFPs) via externalized cables in 38 patients with PD (35 reporting FOG in daily life ...
Antoine Collomb‐Clerc   +12 more
wiley   +1 more source

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy

open access: yesAnnals of Neurology, EarlyView.
Objective Exenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof‐of‐concept clinical trial. Methods In this single‐center, randomized, open label trial, participants with MSA were randomly assigned (1:1) to receive ...
Nirosen Vijiaratnam   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy